NASDAQ:KPRX Kiora Pharmaceuticals (KPRX) Stock Price, News & Analysis → Protect Yourself While There’s Still Time … (From Weiss Ratings) (Ad) Free KPRX Stock Alerts $0.47 -0.01 (-2.08%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$0.47▼$0.5050-Day Range$0.48▼$0.7152-Week Range$0.45▼$5.25Volume117,790 shsAverage Volume1.32 million shsMarket Capitalization$12.34 millionP/E RatioN/ADividend YieldN/APrice Target$7.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get Kiora Pharmaceuticals alerts: Email Address Kiora Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,389.4% Upside$7.00 Price TargetShort InterestHealthy0.31% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.92 out of 5 starsMedical Sector586th out of 913 stocksPharmaceutical Preparations Industry261st out of 421 stocks 3.5 Analyst's Opinion Consensus RatingKiora Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageKiora Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.31% of the float of Kiora Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverKiora Pharmaceuticals has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Kiora Pharmaceuticals has recently increased by 48.28%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldKiora Pharmaceuticals does not currently pay a dividend.Dividend GrowthKiora Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for KPRX. Previous Next 1.1 News and Social Media Coverage News SentimentKiora Pharmaceuticals has a news sentiment score of -1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.32 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Kiora Pharmaceuticals this week, compared to 0 articles on an average week.Search InterestOnly 1 people have searched for KPRX on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows3 people have added Kiora Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Kiora Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.94% of the stock of Kiora Pharmaceuticals is held by insiders.Percentage Held by Institutions76.97% of the stock of Kiora Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Price to Book Value per Share RatioKiora Pharmaceuticals has a P/B Ratio of 0.59. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsProtect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.4 simple steps to protect your privacy and money before it’s too late. About Kiora Pharmaceuticals Stock (NASDAQ:KPRX)Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, and KIO-104 for the treatment of posterior non-infectious uveitis; and KIO-201, an eye drop, which is in Phase 3b clinical trial for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.Read More KPRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart KPRX Stock News HeadlinesApril 18, 2024 | americanbankingnews.comKiora Pharmaceuticals (NASDAQ:KPRX) Trading Down 7.9%March 25, 2024 | msn.comKiora Pharmaceuticals reports FY resultsApril 27, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.February 9, 2024 | markets.businessinsider.comKiora Pharmaceuticals: Strong Buy Rating on Strategic Partnership and Promising Trial ResultsFebruary 9, 2024 | markets.businessinsider.comHC Wainwright & Co. Maintains Buy Rating for Kiora Pharmaceuticals: Here's What You Need To KnowFebruary 1, 2024 | msn.comWhat's Going On With Kiora Pharmaceuticals Stock?February 1, 2024 | benzinga.comWhy Nextracker Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving PremarketFebruary 1, 2024 | msn.comWhy Is Kiora Pharmaceuticals (KPRX) Stock Up 39% Today?April 27, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.January 31, 2024 | msn.comKiora stock soars after hours on deal with Thea Open InnovationJanuary 31, 2024 | finance.yahoo.comKiora Pharmaceuticals and Théa Open Innovation Enter Strategic Agreement to Develop and Commercialize KIO-301 for the Treatment of Inherited Retinal Diseases; Total Deal Value of up to $301 Million includes $16 Million Upfront, up to $285 Million in Clinical Development, Regulatory and Commercial Milestones, Plus Commercial RoyaltiesJanuary 31, 2024 | finance.yahoo.comKiora Pharmaceuticals Announces Private Placement of up to Approximately $45 MillionJanuary 9, 2024 | morningstar.comKiora Pharmaceuticals Inc KPRXNovember 17, 2023 | finance.yahoo.comBreaking ground in vision restoration: Kiora Pharmaceuticals reveals promising results with KIO-301November 11, 2023 | benzinga.comKiora Pharmaceuticals Stock (NASDAQ:KPRX) Earnings Dates and Earning CallsNovember 9, 2023 | msn.comKiora Pharmaceuticals reports Q3 resultsNovember 9, 2023 | finance.yahoo.comKiora Pharmaceuticals Reports Q3 2023 Results; Expanding Clinical Development of KIO-301 for Inherited Retinal Diseases Based on Encouraging Results of ABACUS-1 Study in Retinitis PigmentosaNovember 8, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Cassava Sciences (SAVA), Kiora Pharmaceuticals (KPRX) and Bluebird Bio (BLUE)November 6, 2023 | markets.businessinsider.comAnalyst Expectations for Kiora Pharmaceuticals's FutureNovember 4, 2023 | finance.yahoo.comAAO Late-Breaking: Kiora's Small Molecule Photoswitch Demonstrates Meaningful Vision Improvements in Blind Patients with Retinitis PigmentosaOctober 16, 2023 | finance.yahoo.comKiora Pharmaceuticals to Participate in the Lytham Partners Fall 2023 Investor ConferenceOctober 3, 2023 | finance.yahoo.comKiora Pharmaceuticals Receives Investigational New Drug Application Approval to Expand Phase 1b Study of KIO-301 in Inherited Retinal Diseases; To Enroll Patients with Choroideremia and Additional Patients with Late-Stage Retinitis PigmentosaSeptember 21, 2023 | finance.yahoo.comKiora Pharmaceuticals Appoints Praveen Tyle, PhD, as New Chairman; Succeeds Paul Chaney Who is Retiring After Serving 17 YearsSeptember 18, 2023 | finance.yahoo.comKiora Pharmaceuticals Completes Last Patient, Last Visit in Phase 1B Trial of KIO-301 in Patients with Retinitis PigmentosaSeptember 14, 2023 | finance.yahoo.comKiora Pharmaceuticals to Present Topline Results from the ABACUS Study at American Academy Ophthalmology (AAO); Phase 1b Study Evaluating KIO-301 in Retinitis PigmentosaSeptember 1, 2023 | finance.yahoo.comKiora Pharmaceuticals Adjourns Special Meeting of Stockholders to September 27August 29, 2023 | finance.yahoo.comKiora Pharmaceuticals and the Choroideremia Research Foundation to Host Webinar on the Development of Molecular Photoswitches for Inherited Retinal DiseasesSee More Headlines Receive KPRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kiora Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/15/2021Today4/26/2024Next Earnings (Estimated)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:KPRX CUSIPN/A CIK1372514 Webeyegatepharma.com Phone(781) 788-9043FaxN/AEmployees12Year FoundedN/APrice Target and Rating Average Stock Price Target$7.00 High Stock Price Target$7.00 Low Stock Price Target$7.00 Potential Upside/Downside+1,389.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-12,510,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-131.68% Return on Assets-75.82% Debt Debt-to-Equity RatioN/A Current Ratio2.90 Quick Ratio2.90 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.79 per share Price / Book0.59Miscellaneous Outstanding Shares26,260,000Free Float26,009,000Market Cap$12.34 million OptionableNot Optionable Beta-0.26 Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesDr. Brian M. Strem Ph.D. (Age 44)President, CEO & Director Comp: $464.93kDr. Eric J. Daniels M.B.A. (Age 50)M.D., Chief Development Officer Comp: $371.47kDr. Stefan Sperl Ph.D.Executive Vice President of CMC & OperationsKey CompetitorsAytu BioPharmaNASDAQ:AYTUNeuroBo PharmaceuticalsNASDAQ:NRBOCocrystal PharmaNASDAQ:COCPTetraphase PharmaceuticalsNASDAQ:TTPHTalpheraNASDAQ:TLPHView All CompetitorsInstitutional OwnershipRosalind Advisors Inc.Bought 2,300,000 shares on 4/25/2024Ownership: 8.759%View All Institutional Transactions KPRX Stock Analysis - Frequently Asked Questions Should I buy or sell Kiora Pharmaceuticals stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Kiora Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" KPRX shares. View KPRX analyst ratings or view top-rated stocks. What is Kiora Pharmaceuticals' stock price target for 2024? 1 Wall Street research analysts have issued 12-month target prices for Kiora Pharmaceuticals' shares. Their KPRX share price targets range from $7.00 to $7.00. On average, they expect the company's share price to reach $7.00 in the next twelve months. This suggests a possible upside of 1,389.4% from the stock's current price. View analysts price targets for KPRX or view top-rated stocks among Wall Street analysts. How have KPRX shares performed in 2024? Kiora Pharmaceuticals' stock was trading at $0.5224 at the beginning of the year. Since then, KPRX stock has decreased by 10.0% and is now trading at $0.47. View the best growth stocks for 2024 here. Are investors shorting Kiora Pharmaceuticals? Kiora Pharmaceuticals saw a increase in short interest in April. As of April 15th, there was short interest totaling 73,400 shares, an increase of 48.3% from the March 31st total of 49,500 shares. Based on an average trading volume of 1,630,000 shares, the days-to-cover ratio is currently 0.0 days. Currently, 0.3% of the company's stock are short sold. View Kiora Pharmaceuticals' Short Interest. When is Kiora Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our KPRX earnings forecast. How were Kiora Pharmaceuticals' earnings last quarter? Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) issued its quarterly earnings data on Monday, November, 15th. The company reported ($11.60) EPS for the quarter, topping analysts' consensus estimates of ($13.48) by $1.88. When did Kiora Pharmaceuticals' stock split? Kiora Pharmaceuticals shares reverse split on Tuesday, September 27th 2022. The 1-40 reverse split was announced on Tuesday, September 27th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, September 27th 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. Who are Kiora Pharmaceuticals' major shareholders? Kiora Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Rosalind Advisors Inc. (8.76%). How do I buy shares of Kiora Pharmaceuticals? Shares of KPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:KPRX) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithFed launches fourth dollar overhaulStansberry ResearchBiden out June 13; Kamala won’t replace him?Paradigm PressMan Who Predicted 2008: “This Will be Worse.”AltimetryExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kiora Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
